Abstract
Secreted phospholipases A2 (sPLA2) are suggested to play an important role in inflammation and tumorigenesis. Different mechanisms of epigenetic regulation are involved in the control of group IIA, III and X sPLA2s expression in cancer cells, but group V sPLA2 (GV-PLA2) in this respect has not been studied. Here, we demonstrate the role of epigenetic mechanisms in regulation of GV-PLA2 expression in different cell lines originating from leukaemia and solid cancers. In blood leukocytes from leukaemic patients, levels of GV-PLA2 transcripts were significantly lower in comparison to those from healthy individuals. Similarly, in DU-145 and PC-3 prostate and CAL-51 and MCF-7 mammary cancer cell lines, levels of GV-PLA2 transcripts were significantly lower in relation to those found in normal epithelial cells of prostate or mammary. By sequencing and methylation-specific high-resolution melting (MS-HRM) analyses of bisulphite-modified DNA, distinct CpG sites in the GV-PLA2 promoter region were identified that were differentially methylated in cancer cells in comparison to normal epithelial and endothelial cells. Spearman rank order analysis revealed a significant negative correlation between the methylation degree and the cellular expression of GV-PLA2 (r = −0.697; p = 0.01). The effects of demethylating agent (5-aza-2′-deoxycytidine) and histone deacetylase inhibitor (trichostatin A) on GV-PLA2 transcription in the analysed cells confirmed the importance of DNA methylation and histone modification in the regulation of the GV-PLA2 gene expression in leukaemic, prostate and mammary cancer cell lines. The exposure of tumour cells to human recombinant GV-PLA2 resulted in a reduced colony forming activity of MCF-7, HepG2 and PC-3 cells, but not of DU-145 cells suggesting a cell-type-dependent effect of GV-PLA2 on cell growth. In conclusion, our results suggest that epigenetic mechanisms such as DNA methylation and histone modification play an important role in downregulation of GV-PLA2 expression in cancer cells.
Similar content being viewed by others
Abbreviations
- 5-aza-dC:
-
5-Aza-2′-deoxycytidine
- CV:
-
Crystal violet
- DMSO:
-
Dimethyl sulfoxide
- FCS:
-
Foetal calf serum
- GV-PLA2 :
-
Group V secreted phospholipase A2
- HCAEC:
-
Human coronary artery endothelial cells
- HUVEC:
-
Human umbilical vein endothelial cells
- MAPK:
-
Mitogen-activated protein kinase
- MS-HRM:
-
Methylation-specific high-resolution melting
- PBS:
-
Phosphate-buffered saline
- PCR:
-
Polymerase chain reaction
- RT-qPCR:
-
Real-time quantitative PCR
- SEM:
-
Standard error of the mean
- sPLA2 :
-
Secreted phospholipase A2
- TSA:
-
Trichostatin A
References
Dennis EA, Deems RA, Yu L. Extracellular phospholipase A2. Adv Exp Med Biol. 1992;318:35–9.
Murakami M, Lambeau G. Emerging roles of secreted phospholipase A2 enzymes: an update. Biochimie. 2013;95:43–50.
Menschikowski M, Hagelgans A, Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat. 2006;79:1–33.
Chen J, Engle SJ, Seilhamer JJ, Tischfield JA. Cloning and recombinant expression of a novel human low molecular weight Ca2+-dependent phospholipase A2. J Biol Chem. 1994;269:2365–8.
Xue M, Shen K, McKelvey K, Li J, Chan YK, Hatzis V, et al. Endothelial protein C receptor associated invasiveness of rheumatoid synovial fibroblasts is likely driven by group V secretory phospholipase A2. Arthritis Res Ther. 2014;16:R44.
Rosengren B, Peilot H, Umaerus M, Jönsson-Rylander AC, Mattsson-Hultén L, Hallberg C, et al. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans and induction in aorta by a western diet. Arterioscler Thromb Vasc Biol. 2006;26:1579–85.
Sonoki K, Iwase M, Ohdo S, Ieiri I, Matsuyama N, Takata Y, et al. Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNFα-stimulated human endothelial cells and reduce associated atherogenicity. J Cardiovasc Pharmacol. 2012;60:367–74.
Muñoz NM, Desai A, Meliton LN, Meliton AY, Zhou T, Leff AR, et al. Group V phospholipase A2 increases pulmonary endothelial permeability through direct hydrolysis of the cell membrane. Pulm Circ. 2012;2:182–92.
Rosenson RS, Gelb MH. Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Curr Cardiol Rep. 2009;11:445–51.
Balestrieri B, Arm JP. Group V sPLA2: classical and novel functions. Biochim Biophys Acta. 2006;1761:1280–8.
Degousee N, Ghomashchi F, Stefanski E, Singer A, Smart BP, Borregaard N, et al. V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem. 2002;277:5061–73.
Kim KP, Rafter JD, Bittova L, Han SK, Snitko Y, Munoz NM, et al. Mechanism of human group V phospholipase A2 (PLA2)-induced leukotriene biosynthesis in human neutrophils. A potential role of heparan sulfate binding in PLA2 internalization and degradation. J Biol Chem. 2001;276:11126–34.
Rubio JM, Rodríguez JP, Gil-de-Gómez L, Guijas C, Balboa MA, Balsinde J. Group V Secreted Phospholipase A2 Is Upregulated by IL-4 in Human Macrophages and Mediates Phagocytosis via Hydrolysis of Ethanolamine Phospholipids. J Immunol. 2015;194:3327–39.
Boilard E, Lai Y, Larabee K, Balestrieri B, Ghomashchi F, Fujioka D, et al. A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. EMBO Mol Med. 2010;2:172–87.
Murakami M, Sato H, Miki Y, Yamamoto K, Taketomi Y. A New Era of Secreted Phospholipase A2 (sPLA2). J Lipid Res. 2015;56:1248–61.
Ito M, Ishikawa Y, Kiguchi H, Komiyama K, Murakami M, Kudo I, et al. Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease. J Gastroenterol Hepatol. 2004;19:1140–9.
Masuda S, Murakami M, Ishikawa Y, Ishii T, Kudo I. Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues. Biochim Biophys Acta. 2005;1736:200–10.
Scott KF, Sajinovic M, Hein J, Nixdorf S, Galettis P, Liauw W, et al. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie. 2010;92:601–10.
Quach ND, Arnold RD, Cummings BS. Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease. Biochem Pharmacol. 2014;90:338–48.
Brglez V, Lambeau G, Petan T. Secreted phospholipases A2 in cancer: diverse mechanisms of action. Biochimie. 2014;107:114–23.
Mounier CM, Wendum D, Greenspan E, Fléjou JF, Rosenberg DW, Lambeau G. Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br J Cancer. 2008;98:587–95.
Fiancette R, Vincent C, Donnard M, Bordessoule D, Turlure P, Trimoreau F, et al. Genes encoding multiple forms of phospholipase A2 are expressed in immature forms of human leukemic blasts. Leukemia. 2009;23:1196–9.
Menschikowski M, Hagelgans A, Kostka H, Eisenhofer G, Siegert G. Involvement of epigenetic mechanisms in the regulation of secreted phospholipase A2 expressions in Jurkat leukemia cells. Neoplasia. 2008;10:1195–203.
Gorovetz M, Baekelandt M, Berner A, Trope’ CG, Davidson B, Reich R. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gynecol Oncol. 2006;103:831–40.
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–54.
Toiyama Y, Okugawa Y, Goel A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun. 2014;455:43–57.
Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley EL, Siegert G. Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia. 2008;10:279–86.
Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res. 2008;68:4277–86.
Brglez V, Pucer A, Pungerčar J, Lambeau G, Petan T. Secreted phospholipases A2 are differentially expressed and epigenetically silenced in human mammary cancer cells. Biochem Biophys Res Commun. 2014;445:230–5.
Lacroux C, Vilette D, Fernández-Borges N, Litaise C, Lugan S, Morel N, et al. Prionemia and leukocyte-platelet-associated infectivity in sheep transmissible spongiform encephalopathy models. J Virol. 2012;86:2056–66.
McCurdy RD, McGrath JJ, Mackay-Sim A. Validation of the comparative quantification method of real-time PCR analysis and a cautionary tale of housekeeping gene selection. Gene Ther Mol Biol. 2008;12:15–24.
Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427–31.
Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, Albà MM, et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003;31:3651–3.
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–80.
Ben-Hattar J, Jiricny J. Methylation of single CpG dinucleotides within a promoter element of the Herpes simplex virus tk gene reduces its transcription in vivo. Gene. 1988;65:219–27.
Douet V, Heller MB, Le Saux O. DNA methylation and Sp1 binding determine the tissue-specific transcriptional activity of the mouse Abcc6 promoter. Biochem Biophys Res Commun. 2007;354:66–71.
Zou B, Chim CS, Zeng H, Leung SY, Yang Y, Tu SP, et al. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology. 2006;131:1835–43.
Miki Y, Mukae S, Murakami M, Ishikawa Y, Ishii T, Ohki H, et al. Butyrate inhibits oral cancer cell proliferation and regulates expression of secretory phospholipase A2-X and COX-2. Anticancer Res. 2007;27:1493–502.
Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(Suppl):245–54.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.
Menschikowski M, Platzbecker U, Hagelgans A, Vogel M, Thiede C, Schönefeldt C, et al. Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells. BMC Cancer. 2012;12:576.
Bernard D, Vindrieux D. PLA2R1: expression and function in cancer. Biochim Biophys Acta. 1846;2014:40–4.
Surrel F, Jemel I, Boilard E, Bollinger JG, Payré C, Mounier CM, et al. Group X phospholipase A2 stimulates the proliferation of colon cancer cells by producing various lipid mediators. Mol Pharmacol. 2009;76:778–90.
Pucer A, Brglez V, Payré C, Pungerčar J, Lambeau G, Petan T. Group X secreted phospholipase A2 induces lipid droplet formation and prolongs breast cancer cell survival. Mol Cancer. 2013;12:111.
Martín R, Cordova C, Nieto ML. Secreted phospholipase A2-IIA-induced a phenotype of activated microglia in BV-2 cells requires epidermal growth factor receptor transactivation and proHB-EGF shedding. J Neuroinflammation. 2012;9:154.
Henderson Jr WR, Ye X, Lai Y, Ni Z, Bollinger JG, Tien YT, et al. Key role of group V secreted phospholipase A2 in Th2 cytokine and dendritic cell-driven airway hyperresponsiveness and remodeling. PLoS One. 2013;8:e56172.
Murakami M, Kambe T, Shimbara S, Higashino K, Hanasaki K, Arita H, et al. Different functional aspects of the group II subfamily (Types IIA and V) and type X secretory phospholipase A2s in regulating arachidonic acid release and prostaglandin generation. Implications of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular membrane perturbation. J Biol Chem. 1999;274:31435–44.
Acknowledgments
The authors are grateful to Dr. Sylke Winkler, Liane Funke and Dorit Pache for performing DNA sequencing with ABI 3.1 at the 3730 XL ABI Hitachi-sequencer (Max Planck Institute of Molecular Cell Biology and Genetics, DNA Sequencing Facility, Dresden) and to Margot Vogel and Romy Adler for their expert technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Figure S1
(DOC 993 kb)
Supplementary Table S1
(DOC 51 kb)
Supplementary Table S2
(DOC 35 kb)
Rights and permissions
About this article
Cite this article
Menschikowski, M., Hagelgans, A., Nacke, B. et al. Epigenetic control of group V phospholipase A2 expression in human malignant cells. Tumor Biol. 37, 8097–8105 (2016). https://doi.org/10.1007/s13277-015-4670-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-015-4670-x